|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2019. CA Cancer J Clin. 69:7–34. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Sharma SV, Bell DW, Settleman J and Haber
DA: Epidermal growth factor receptor mutations in lung cancer. Nat
Rev Cancer. 7:169–181. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
3
|
Yu HA, Arcila ME, Rekhtman N, Sima CS,
Zakowski MF, Pao W, Kris MG, Miller VA, Ladanyi M and Riely GJ:
Analysis of tumor specimens at the time of acquired resistance to
EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers.
Clin Cancer Res. 19:2240–2247. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Siegel RL, Miller KD, Fuchs HE and Jemal
A: Cancer statistics, 2022. CA Cancer J Clin. 72:7–33. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Chen ZQ, Huang LS and Zhu B: Assessment of
seven clinical tumor markers in diagnosis of non-small-cell lung
cancer. Dis Markers. 2018:98451232018. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wen Z, Huang Y, Ling Z, Chen J, Wei X, Su
R, Tang Z, Wen Z, Deng Y and Hu Z: Lack of efficacy of combined
carbohydrate antigen markers for lung cancer diagnosis. Dis
Markers. 2020:47167932020. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lamy PJ, Grenier J, Kramar A and Pujol JL:
Pro-gastrin-releasing peptide, neuron specific enolase and
chromogranin A as serum markers of small cell lung cancer. Lung
Cancer. 29:197–203. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kjellev S: The trefoil factor family-small
peptides with multiple functionalities. Cell Mol Life Sci.
66:1350–1369. 2009. View Article : Google Scholar
|
|
9
|
Thim L: Trefoil peptides: From structure
to function. Cell Mol Life Sci. 53:888–903. 1997. View Article : Google Scholar
|
|
10
|
Xiao P, Ling H, Lan G, Liu J, Hu H and
Yang R: Trefoil factors: Gastrointestinal-specific proteins
associated with gastric cancer. Clin Chim Acta. 450:127–134. 2015.
View Article : Google Scholar
|
|
11
|
Arumugam T, Brandt W, Ramachandran V,
Moore TT, Wang H, May FE, Westley BR, Hwang RF and Logsdon CD:
Trefoil factor 1 stimulates both pancreatic cancer and stellate
cells and increases metastasis. Pancreas. 40:815–822. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Rodrigues S, Rodrigue CM, Attoub S, Flejou
JF, Bruyneel E, Bracke M, Emami S and Gespach C: Induction of the
adenoma-carcinoma progression and Cdc25A-B phosphatases by the
trefoil factor TFF1 in human colon epithelial cells. Oncogene.
25:6628–6636. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yusufu A, Shayimu P, Tuerdi R, Fang C,
Wang F and Wang H: TFF3 and TFF1 expression levels are elevated in
colorectal cancer and promote the malignant behavior of colon
cancer by activating the EMT process. Int J Oncol. 55:789–804.
2019.
|
|
14
|
Kannan N, Kang J, Kong X, Tang J, Perry
JK, Mohankumar KM, Miller LD, Liu ET, Mertani HC, Zhu T, et al:
Trefoil factor 3 is oncogenic and mediates anti-estrogen resistance
in human mammary carcinoma. Neoplasia. 12:1041–1053. 2010.
View Article : Google Scholar
|
|
15
|
Pandey V, Wu ZS, Zhang M, Li R, Zhang J,
Zhu T and Lobie PE: Trefoil factor 3 promotes metastatic seeding
and predicts poor survival outcome of patients with mammary
carcinoma. Breast Cancer Res. 16:4292014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Taupin DR, Kinoshita K and Podolsky DK:
Intestinal trefoil factor confers colonic epithelial resistance to
apoptosis. Proc Natl Acad Sci USA. 97:799–804. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ishibashi Y, Ohtsu H, Ikemura M, Kikuchi
Y, Niwa T, Nishioka K, Uchida Y, Miura H, Aikou S, Gunji T, et al:
Serum TFF1 and TFF3 but not TFF2 are higher in women with breast
cancer than in women without breast cancer. Sci Rep. 7:48462017.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ruibal A, Nunez MI, del Rio MC, Garcia
Diez S, Rodriguez J and Alvarez De Linera JA: Cytosolic pS2 levels
in 154 non-small-cell lung carcinomas. Correlation with other
clinical and biological parameters. Rev Esp Med Nucl. 21:109–114.
2002.(In Spanish). View Article : Google Scholar
|
|
19
|
Amelung JT, Buhrens R, Beshay M and
Reymond MA: Key genes in lung cancer translational research: A
meta-analysis. Pathobiology. 77:53–63. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ohshio G, Suwa H, Kawaguchi Y, Imamura M,
Yamaoka Y, Yamabe H, Matsumoto M, Yoshioka H, Hashimoto Y and
Takeda H: Differential expression of human spasmolytic polypeptide
(trefoil factor family-2) in pancreatic carcinomas, ampullary
carcinomas, and mucin-producing tumors of the pancreas. Dig Dis
Sci. 45:659–664. 2000. View Article : Google Scholar
|
|
21
|
John R, El-Rouby NM, Tomasetto C, Rio MC
and Karam SM: Expression of TFF3 during multistep colon
carcinogenesis. Histol Histopathol. 22:743–751. 2007.
|
|
22
|
Dhar DK, Wang TC, Maruyama R, Udagawa J,
Kubota H, Fuji T, Tachibana M, Ono T, Otani H and Nagasue N:
Expression of cytoplasmic TFF2 is a marker of tumor metastasis and
negative prognostic factor in gastric cancer. Lab Invest.
83:1343–1352. 2003. View Article : Google Scholar
|
|
23
|
Dhar DK, Wang TC, Tabara H, Tonomoto Y,
Maruyama R, Tachibana M, Kubota H and Nagasue N: Expression of
trefoil factor family members correlates with patient prognosis and
neoangiogenesis. Clin Cancer Res. 11:6472–6478. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yamachika T, Werther JL, Bodian C,
Babyatsky M, Tatematsu M, Yamamura Y, Chen A and Itzkowitz S:
Intestinal trefoil factor: A marker of poor prognosis in gastric
carcinoma. Clin Cancer Res. 8:1092–1099. 2002.PubMed/NCBI
|
|
25
|
Yang Y, Lin Z, Lin Q, Bei W and Guo J:
Pathological and therapeutic roles of bioactive peptide trefoil
factor 3 in diverse diseases: Recent progress and perspective. Cell
Death Dis. 13:622022. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Babyatsky M, Lin J, Yio X, Chen A, Zhang
JY, Zheng Y, Twyman C, Bao X, Schwartz M, Thung S, et al: Trefoil
factor-3 expression in human colon cancer liver metastasis. Clin
Exp Metastasis. 26:143–151. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ahmed ARH, Griffiths AB, Tilby MT, Westley
BR and May FEB: TFF3 is a normal breast epithelial protein and is
associated with differentiated phenotype in early breast cancer but
predisposes to invasion and metastasis in advanced disease. Am J
Pathol. 180:904–916. 2012. View Article : Google Scholar
|
|
28
|
Buache E, Etique N, Alpy F, Stoll I,
Muckensturm M, Reina-San-Martin B, Chenard MP, Tomasetto C and Rio
MC: Deficiency in trefoil factor 1 (TFF1) increases tumorigenicity
of human breast cancer cells and mammary tumor development in
TFF1-knockout mice. Oncogene. 30:3261–3273. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Bossenmeyer-Pourie C, Kannan R, Ribieras
S, Wendling C, Stoll I, Thim L, Tomasetto C and Rio MC: The trefoil
factor 1 participates in gastrointestinal cell differentiation by
delaying G1-S phase transition and reducing apoptosis. J Cell Biol.
157:761–770. 2002. View Article : Google Scholar
|
|
30
|
Minegishi K, Dobashi Y, Tsubochi H,
Hagiwara K, Ishibashi Y, Nomura S, Nakamura R, Ohmoto Y and Endo S:
TFF-1 functions to suppress multiple phenotypes associated with
lung cancer progression. Onco Targets Ther. 14:4761–4777. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Thompson AM, Elton RA, Hawkins RA, Chetty
U and Steel CM: PS2 mRNA expression adds prognostic information to
node status for 6-year survival in breast cancer. Br J Cancer.
77:492–496. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Uchino H, Kataoka H, Itoh H, Hamasuna R
and Koono M: Overexpression of intestinal trefoil factor in human
colon carcinoma cells reduces cellular growth in vitro and in vivo.
Gastroenterology. 118:60–69. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Espinoza I, Agarwal S, Reddy A, Shenoy V,
Subramony C, Sakiyama M, Fair L, Poosarla T, Zhou X, Shannon Orr W,
et al: Expression of trefoil factor 3 is decreased in colorectal
cancer. Oncol Rep. 45:254–264. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Huang Z, Zhang X, Lu H, Wu L, Wang D,
Zhang Q and Ding H: Serum trefoil factor 3 is a promising
non-invasive biomarker for gastric cancer screening: A monocentric
cohort study in China. BMC Gastroenterol. 14:742014. View Article : Google Scholar
|
|
35
|
Aikou S, Ohmoto Y, Gunji T, Matsuhashi N,
Ohtsu H, Miura H, Kubota K, Yamagata Y, Seto Y, Nakajima A, et al:
Tests for serum levels of trefoil factor family proteins can
improve gastric cancer screening. Gastroenterology. 141:837–845.
e1–7. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Vocka M, Langer D, Petrtyl J, Vockova P,
Hanus T, Kalousova M, Zima T and Petruzelka L: Trefoil factor
family (TFF) proteins as potential serum biomarkers in patients
with metastatic colorectal cancer. Neoplasma. 62:470–477. 2015.
View Article : Google Scholar
|
|
37
|
Bignotti E, Ravaggi A, Tassi RA, Calza S,
Rossi E, Falchetti M, Romani C, Bandiera E, Odicino FE, Pecorelli S
and Santin AD: Trefoil factor 3: A novel serum marker identified by
gene expression profiling in high-grade endometrial carcinomas. Br
J Cancer. 99:768–773. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Vestergaard EM, Borre M, Poulsen SS, Nexo
E and Torring N: Plasma levels of trefoil factors are increased in
patients with advanced prostate cancer. Clin Cancer Res. 12((3 Pt
1)): 807–812. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Im S, Yoo C, Jung JH, Choi HJ, Yoo J and
Kang CS: Reduced expression of TFF1 and increased expression of
TFF3 in gastric cancer: Correlation with clinicopathological
parameters and prognosis. Int J Med Sci. 10:133–140. 2013.
View Article : Google Scholar
|
|
40
|
Casado E, Garcia VM, Sanchez JJ, Gomez Del
Pulgar MT, Feliu J, Maurel J, Castelo B, Moreno Rubio J, Lopez RA,
Garcia-Cabezas MA, et al: Upregulation of trefoil factor 3 (TFF3)
after rectal cancer chemoradiotherapy is an adverse prognostic
factor and a potential therapeutic target. Int J Radiat Oncol Biol
Phys. 84:1151–1158. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Li Q, Wang K, Su C and Fang J: Serum
Trefoil Factor 3 as a protein biomarker for the diagnosis of
colorectal cancer. Technol Cancer Res Treat. 16:440–445. 2017.
View Article : Google Scholar
|
|
42
|
Qu Y, Yang Y, Ma D and Xiao W: Increased
trefoil factor 3 levels in the serum of patients with three. Oncol
Rep. 27:1277–1283. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Amin MB, Greene FL, Edge SB, Compton CC,
Gershenwald JE, Brookland RK, Meyer L, Gress DM, Byrd DR and
Winchester DP: The Eighth Edition AJCC Cancer Staging Manual:
Continuing to build a bridge from a population-based to a more
‘personalized’ approach to cancer staging. CA Cancer J Clin.
67:93–99. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Dobashi Y, Tsubochi H, Matsubara H, Inoue
J, Inazawa J, Endo S and Ooi A: Diverse involvement of isoforms and
gene aberrations of Akt in human lung carcinomas. Cancer Sci.
106:772–781. 2015. View Article : Google Scholar
|
|
45
|
Ribieras S, Tomasetto C and Rio MC: The
pS2/TFF1 trefoil factor, from basic research to clinical
applications. Biochim Biophys Acta. 1378:F61–F77. 1998.
|
|
46
|
Xue H, Lu B, Zhang J, Wu M, Huang Q, Wu Q,
Sheng H, Wu D, Hu J and Lai M: Identification of serum biomarkers
for colorectal cancer metastasis using a differential secretome
approach. J Proteome Res. 9:545–555. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Chen RM, Chiou YS, Chong QY, Poh HM, Tan
TZ, Zhang MY, Ma L, Zhu T, Pandey V, Basappa, Kumar AP and Lobie
PE: Pharmacological Inhibition of TFF3 Enhances Sensitivity of CMS4
Colorectal Carcinoma to 5-Fluorouracil through Inhibition of p44/42
MAPK. Int J Mol Sci. 20:62152019. View Article : Google Scholar
|
|
48
|
Yusup A, Huji B, Fang C, Wang F, Dadihan
T, Wang HJ and Upur H: Expression of trefoil factors and TWIST1 in
colorectal cancer and their correlation with metastatic potential
and prognosis. World J Gastroenterol. 23:110–120. 2017. View Article : Google Scholar
|
|
49
|
Xie H, Guo JH, An WM, Tian ST, Yu HP, Yang
XL, Wang HM and Guo Z: Diagnostic value evaluation of trefoil
factors family 3 for the early detection of colorectal cancer.
World J Gastroenterol. 23:2159–2167. 2017. View Article : Google Scholar
|
|
50
|
Kaise M, Miwa J, Tashiro J, Ohmoto Y,
Morimoto S, Kato M, Urashima M, Ikegami M and Tajiri H: The
combination of serum trefoil factor 3 and pepsinogen testing is a
valid non-endoscopic biomarker for predicting the presence of
gastric cancer: A new marker for gastric cancer risk. J
Gastroenterol. 46:736–745. 2011. View Article : Google Scholar
|
|
51
|
Huang YG, Li YF, Wang LP and Zhang Y:
Aberrant expression of trefoil factor 3 is associated with
colorectal carcinoma metastasis. J Cancer Res Ther. 9:376–380.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Xiao L, Liu YP, Xiao CX, Ren JL and Guleng
B: Serum TFF3 may be a pharamcodynamic marker of responses to
chemotherapy in gastrointestinal cancers. BMC Clin Pathol.
14:262014. View Article : Google Scholar
|
|
53
|
Higashiyama M, Doi O, Kodama K, Yokuchi H,
Inaji H and Tateishi R: Estimation of serum level of pS2 protein in
patients with lung adenocarcinoma. Anticancer Res. 16:2351–2355.
1996.PubMed/NCBI
|
|
54
|
Swensen SJ, Jett JR, Hartman TE, Midthun
DE, Sloan JA, Sykes AM, Aughenbaugh GL and Clemens MA: Lung cancer
screening with CT: Mayo Clinic experience. Radiology. 226:756–761.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Sone S, Li F, Yang ZG, Honda T, Maruyama
Y, Takashima S, Hasegawa M, Kawakami S, Kubo K, Haniuda M and
Yamanda T: Results of three-year mass screening programme for lung
cancer using mobile low-dose spiral computed tomography scanner. Br
J Cancer. 84:25–32. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Swensen SJ, Jett JR, Sloan JA, Midthun DE,
Hartman TE, Sykes AM, Aughenbaugh GL, Zink FE, Hillman SL, Noetzel
GR, et al: Screening for lung cancer with low-dose spiral computed
tomography. Am J Respir Crit Care Med. 165:508–513. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Manser RL, Irving LB, de Campo MP,
Abramson MJ, Stone CA, Pedersen KE, Elwood M and Campbell DA:
Overview of observational studies of low-dose helical computed
tomography screening for lung cancer. Respirology. 10:97–104. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Pastorino U: Lung cancer screening. Br J
Cancer. 102:1681–1686. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
dos Santos Silva E, Ulrich M, Doring G,
Botzenhart K and Gott P: Trefoil factor family domain peptides in
the human respiratory tract. J Pathol. 190:133–142. 2000.
View Article : Google Scholar
|
|
60
|
Wiede A, Jagla W, Welte T, Kohnlein T,
Busk H and Hoffmann W: Localization of TFF3, a new mucus-associated
peptide of the human respiratory tract. Am J Respir Crit Care Med.
159((4 Pt 1)): 1330–1335. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Wang DG, Johnston CF, Liu WH, Sloan JM and
Buchanan KD: Expression of a breast-cancer-associated protein (pS2)
in human neuro-endocrine tumours. Int J Cancer. 74:270–274. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Ruchaud-Sparagano MH, Westley BR and May
FE: The trefoil protein TFF1 is bound to MUC5AC in human gastric
mucosa. Cell Mol Life Sci. 61:1946–1954. 2004. View Article : Google Scholar
|
|
63
|
Otto WR and Thim L: Trefoil factor
family-interacting proteins. Cell Mol Life Sci. 62:2939–2946. 2005.
View Article : Google Scholar
|
|
64
|
Kouznetsova I, Laubinger W, Kalbacher H,
Kalinski T, Meyer F, Roessner A and Hoffmann W: Biosynthesis of
gastrokine-2 in the human gastric mucosa: Restricted spatial
expression along the antral gland axis and differential interaction
with TFF1, TFF2 and mucins. Cell Physiol Biochem. 20:899–908. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Sturmer R, Muller S, Hanisch FG and
Hoffmann W: Porcine gastric TFF2 is a mucus constituent and differs
from pancreatic TFF2. Cell Physiol Biochem. 33:895–904. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Hoffmann W: Trefoil factor family (TFF)
peptides and their diverse molecular functions in mucus barrier
protection and more: Changing the paradigm. Int J Mol Sci.
21:45352020. View Article : Google Scholar
|
|
67
|
Koh MJ, Shin DH, Lee SJ, Hwang CS, Lee HJ,
Kim A, Park WY, Lee JH, Choi KU, Kim JY, et al: Gastric-type gene
expression and phenotype in non-terminal respiratory unit type
adenocarcinoma of the lung with invasive mucinous adenocarcinoma
morphology. Histopathology. 76:898–905. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Ge H, Gardner J, Wu X, Rulifson I, Wang J,
Xiong Y, Ye J, Belouski E, Cao P, Tang J, et al: Trefoil Factor 3
(TFF3) is regulated by food intake, improves glucose tolerance and
induces mucinous metaplasia. PLoS One. 10:e01269242015. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Baus-Loncar M, Schmid J, Lalani el-N,
Rosewell I, Goodlad RA, Stamp GW, Blin N and Kayademir T: Trefoil
factor 2 (TFF2) deficiency in murine digestive tract influences the
immune system. Cell Physiol Biochem. 16:31–42. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Itoh H, Tomita M, Uchino H, Kobayashi T,
Kataoka H, Sekiya R and Nawa Y: cDNA cloning of rat pS2 peptide and
expression of trefoil peptides in acetic acid-induced colitis.
Biochem J. 318((Pt 3)): 939–944. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Xian CJ, Howarth GS, Mardell CE, Cool JC,
Familari M, Read LC and Giraud AS: Temporal changes in TFF3
expression and jejunal morphology during methotrexate-induced
damage and repair. Am J Physiol. 277:G785–G795. 1999.
|
|
72
|
Hoffmann W: Trefoil factor family (TFF)
peptides and their links to inflammation: A Re-evaluation and new
medical perspectives. Int J Mol Sci. 22:49092021. View Article : Google Scholar
|
